WARNING
Nephrotoxicity: Bacitracin in parenteral (intramuscular) therapy may cause renal failure due to tubular and glomerular necrosis. Its use should be restricted to infants with staphylococcal pneumonia and empyema when due to organisms shown to be susceptible to bacitracin. It should be used only where adequate laboratory facilities are available and when constant supervision of the patient is possible.
Renal function should be carefully determined prior to and daily during therapy. The recommended daily dose should not be exceeded and fluid intake and urinary output maintained at proper levels to avoid kidney toxicity. If renal toxicity occurs the drug should be discontinued. The concurrent use of other nephrotoxic drugs, particularly streptomycin, kanamycin, polymyxin B, polymyxin E (colistin), neomycin, and viomycin, should be avoided.
|
| |
BACIIM SUMMARY
BACiiM™
Bacitracin for Injection USP
Rx Only
The vial content of Bacitracin for Injection USP is sterile. The therapeutic class of the drug is antibacterial and is intended for intramuscular use.
BACiiM (Bacitracin) is indicated for the following:
In accord with the statements in the “ Warning Box ” the use of intramuscular bacitracin is limited to the treatment of infants with pneumonia and empyema caused by staphylococci shown to be susceptible to the drug.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of bacitracin and other antibacterial drugs, bacitracin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
|
NEWS HIGHLIGHTSMedia Articles Related to Baciim (Bacitracin)
FDA Panel Votes in Favor of New Strep Pneumoniae Vaccine
Source: MedPage Today Infectious Disease [2009.11.18]
BETHESDA, Md. (MedPage Today) -- A Food and Drug Administration (FDA) advisory panel has voted to recommend approval of an updated version of the Streptococcus pneumoniae vaccine Prevnar.
FDA Panel to Vote on Updated Strep pneumoniae Vaccine
Source: MedPage Today Infectious Disease [2009.11.17]
WASHINGTON (MedPage Today) -- A Food and Drug Administration (FDA) advisory panel will decide Wednesday whether to recommend approval of a new version of the popular Streptococcus pneumoniae children's vaccine Prevnar.
Pneumonia Drug Promising Against Form of Muscular Dystrophy
Source: MedicineNet Pneumonia Specialty [2009.11.13]
Title: Pneumonia Drug Promising Against Form of Muscular Dystrophy
Category: Health News
Created: 11/12/2009 2:10:00 PM
Last Editorial Review: 11/13/2009
Inhaled Corticosteroids Boost Pneumonia Risk in COPD
Source: MedicineNet fluticasone and salmeterol oral inhaler Specialty [2009.02.10]
Title: Inhaled Corticosteroids Boost Pneumonia Risk in COPD
Category: Health News
Created: 2/10/2009 2:00:00 AM
Last Editorial Review: 2/10/2009
Pneumonia
Source: MedicineNet Dengue Fever Specialty [2008.04.07]
Title: Pneumonia
Category: Diseases and Conditions
Created: 12/31/1997
Last Editorial Review: 4/7/2008
Published Studies Related to Baciim (Bacitracin)
Effects of dietary mannan oligosaccharide, bacitracin methylene disalicylate, or both on the live performance and intestinal microbiology of turkeys. [2004.07]
Hybrid male turkeys were fed to 18 wk of age in a completely randomized design with 10 replicate pens (18 birds each) per treatment to compare growth promoters. Four dietary treatments were used: negative control (CON), bacitracin methylene disalicyate (BMD) at 55 mg/kg to 6 wk and 27.5 mg/kg thereafter, mannan oligosaccharide (MOS) at 0.1% to 6 wk and 0.05% thereafter, and BMD and MOS at concentrations listed above...
The efficacy of bacitracin methylene disalicylate when fed in combination with narasin in the management of necrotic enteritis in broiler chickens. [2003.03]
The efficacy of bacitracin methylene disalicylate (BMD) in the management of necrotic enteritis (NE) when fed in combination with narasin was investigated in a floor-pen study of 2,000 broiler chickens using a Clostridium perfringens inoculum challenge model.
Evaluation of zinc bacitracin capsules versus placebo for enteric eradication of vancomycin-resistant Enterococcus faecium. [2001.08.15]
Patients who are colonized with enteric vancomycin-resistant Enterococcus faecium (VREF) are a major reservoir for transmission of and infection with this organism. In a randomized, controlled study to assess the effectiveness of high-dose bacitracin in the eradication of enteric VREF, 12 patients who were colonized with VREF were randomized to receive placebo (n=6) or orally administered zinc bacitracin (n=6) for 10 days...
Bacitracin versus mupirocin for Staphylococcus aureus nasal colonization. [1999.05]
We performed a randomized prospective study of 5-day treatment with topical mupirocin or bacitracin for the elimination of Staphylococcus aureus nasal colonization in healthcare workers (HCWs). Nasal cultures were obtained from 141 HCWs, 37 (26%) of whom showed S...
Effect of roxarsone and bacitracin methylene disalicylate on the development of immunity to Eimeria in broilers given a live coccidiosis vaccine. [1996.12]
No significant differences in the BW, feed intake, feed conversion, or mortality of broilers that had been vaccinated at 3 d of age with a live coccidiosis vaccine were observed irrespective of whether they had been given roxarsone, bacitracin methylene disalicylate, or both drugs in the feed.It is concluded that roxarsone and bacitracin methylene disalicylate do not interfere with the acquisition of immunity to Eimeria species in broilers.
Clinical Trials Related to Baciim (Bacitracin)
Clinical Evaluation of Bacitracin [Completed]
Polymem vs. Bacitracin/Xeroform in Treating Burn Wounds [Recruiting]
Patients will be screened at the initial visit to the burn center. If the patients are
eligible according to the inclusion/exclusion criteria, consent for the study will be
obtained. One of the investigators will identify two sites that appear to be the same depth
on each patient [1 site Polymen and 1 site bacitracin/xeroform )]. The depth of injury will
be verified as partial thickness using laser doppler. Each site will be at least 4cm x 4cm
in size. One site will be identified for bacitracin/xeroform and one site for Polymen. All
burns will be initially debrided and cleaned according to burn unit protocol. The dressing
will then be applied. All dressings will be covered with cotton gauze and ace wraps. Laser
Doppler will be utilized to determine burn depth at both the trial and control sites. On
each subsequent visit, patients will rate the pain of the dressing change on a 1-10 pain
intensity scale. It will be noted if the wound appears infected or if antibiotics are
prescribed.
The study will end for each patient when the investigator determines that 95% of their burn
has re-epithelized.
Nasospore Stent For Use in Enodscopic Sinus Surgery [Recruiting]
The purpose of this study is to evaluate a stenting material called Nasopore. This is a
synthetic material approved by FDA for use as a stent in postoperative sinus surgery
patients. This study will compare the Nasopore stent to other approved stenting materials.
Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine [Completed]
To determine the safety, effectiveness, and toxicity of topical (local) trifluridine in
treating mucocutaneous (at the nasal, oral, vaginal, and anal openings) Herpes simplex virus
( HSV ) disease that has shown resistance to acyclovir in HIV-infected patients. HSV
infection in patients with AIDS is often associated with skin sores and frequent recurrences.
Treatment with the drug acyclovir results in healing for most patients, but repeated
treatment sometimes results in resistance of the virus to acyclovir. Thus, when this happens,
other treatments need to be used. Trifluridine is an antiviral drug that is used for the
treatment of Herpes infections that occur in the eye. This study attempts to determine if
trifluridine is useful for treating HSV sores that have not healed after treatment with
acyclovir.
Clinical Evaluation of T.R.U.E. TESTŪ : Safety and Efficacy [Recruiting]
We propose an open, prospective, multi-center Phase III study to evaluate the diagnostic
performance and safety of seven new T. R.U. E. Test allergens: Gold sodium thiosulfate,
Hydrocortisone-17-butyrate, Bacitracin, Parthenolide, Methyldibromoglutaronitrile, Disperse
blue 106, and Bronopol. Allergen performance and safety will be evaluated in adult patients
with suspected contact dermatitis, and in adult patients with a known or suspected
sensitization to at least one of the seven allergens.
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Baciim has an overall score of 5. The effectiveness score is 2 and the side effect score is 4. The scores are on ten point scale: 10 - best, 1 - worst.
| | Baciim review by care giver of 28 year old male patient | | | Rating |
| Overall rating: | |   |
| Effectiveness: | | Ineffective |
| Side effects: | | Severe Side Effects | | |
Treatment Info |
| Condition / reason: | | simple laceration |
| Dosage & duration: | | ointment (dosage frequency: topically applied once) for the period of once |
| Other conditions: | | NONE KNOWN |
| Other drugs taken: | | NONE | | |
Reported Results |
| Benefits: | | THIS IS A WIDELY USED COMMON ANTIBIOTIC OINTMENT FOR SUPERFICIAL LACERATIONS |
| Side effects: | | A FULMINATING ALLERGIC REACTION |
| Comments: | | YOUNG MALE WORKING IN A FACTORY CAME TO HEALTH CLINIC WITH A SUPERFICIAL LACERATION ON HIS FINGER - AFTER CLEANSING THE AREA WITH SOAP WATER PEROXIDE BACITRACIN AND A CLEAN DRY DRESSING APPLIED. WORKER CAME BACK THE FOLLOWING DAY WITH THE FINGER SWOLLEN 2XS AND NOW WOUND ENLARGED AND DRAINING. SENT TO ER FOR F/UP TX OF STEROIDS. |
|
|
|
Page last updated: 2009-11-18
|
